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Introduction
In vertebrates, all skeletal muscles of trunk and limbs originate 
from somites, which are formed sequentially in a rostral-caudal 
direction through segmentation of the paraxial mesoderm dur-
ing embryogenesis (Buckingham et al., 2003). In response 
to signals from the neural tube, notochord, and ectoderm, 
  somites further differentiate into ventral-medially positioned 
sclerotome and dorsally located dermatome with the muscle-
forming myotome sandwiched in between (Buckingham et al., 
2003). In myotome, the muscle precursor cells establish their 
myogenic fate to form proliferating myoblasts by selectively 
expressing one or a few myogenic regulatory factors (MRFs). 
Under appropriate conditions, the myoblasts withdraw from the 
cell cycle to differentiate into mononucleated myocytes, which, 
in turn, align with each other and fuse to form multinucleated 
myotubes or myofi  bers.
Muscle stem cells, which are also called muscle satellite 
cells (MSCs), start to form at the late stage of vertebrate embryo 
development (Morgan and Partridge, 2003; Dhawan and Rando, 
2005; Holterman and Rudnicki, 2005; Wagers and Conboy, 2005). 
In the adult, most of the MSCs are quiescent and uniquely located 
between basal lamina and the plasma membrane of the myofi  bers. 
Several molecular markers, including Pax7, c-Met, M-cadherin, 
and CD34, are expressed in quiescent MSCs. In contrast, MyoD 
is not expressed in quiescent MSCs. In response to muscle injury 
or exercise, these quiescent MSCs become activated, as indicated 
by the expression of MyoD, reenter the cell cycle, and actively 
proliferate to form myoblasts. Eventually, these proliferating 
myoblasts irreversibly withdraw from cell cycles, differentiate, and 
fuse with existing myofi  bers. Accumulating evidence indicates 
that myoblasts are the primary cell types responsible for muscle 
regeneration in vivo (Dhawan and Rando, 2005; Holterman and 
Rudnicki, 2005; Wagers and Conboy, 2005).
JAK1–STAT1–STAT3, a key pathway promoting 
proliferation and preventing premature 
differentiation of myoblasts
Luguo Sun,
1 Kewei Ma,
1 Haixia Wang,
1 Fang Xiao,
1 Yan Gao,
1 Wei Zhang,
1 Kepeng Wang,
1 Xiang Gao,
2 
Nancy Ip,
1 and Zhenguo Wu
1
1Department of Biochemistry, Hong Kong University of Science and Technology, Hong Kong, China
2Model Animal Research Center, Nanjing University, Nanjing 210061, China
S
keletal muscle stem cell–derived myoblasts are 
mainly responsible for postnatal muscle growth and 
injury-induced muscle regeneration. However, the 
cellular signaling pathways controlling the proliferation 
and differentiation of myoblasts are not fully understood. 
We demonstrate that Janus kinase 1 (JAK1) is required for 
myoblast proliferation and that it also functions as a check-
point to prevent myoblasts from premature differentiation. 
Deliberate knockdown of JAK1 in both primary and immor-
talized myoblasts induces precocious myogenic differen-
tiation with a concomitant reduction in cell proliferation. 
This is caused, in part, by an accelerated induction of 
MyoD, myocyte enhancer–binding factor 2 (MEF2), 
p21Cip1, and p27Kip1, a faster down-regulation of Id1, 
and an increase in MEF2-dependent gene transcription. 
Downstream of JAK1, of all the signal transducer and 
activator of transcriptions (STATs) present in myoblasts, we 
ﬁ  nd that only STAT1 knockdown promotes myogenic dif-
ferentiation in both primary and immortalized myoblasts. 
Leukemia inhibitory factor stimulates myoblast prolifera-
tion and represses differentiation via JAK1–STAT1–STAT3. 
Thus, JAK1–STAT1–STAT3 constitutes a signaling pathway 
that promotes myoblast proliferation and prevents pre-
mature myoblast differentiation.
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Elucidation of the molecular mechanisms underlying 
myogenic differentiation has been greatly facilitated by the 
availability of several immortalized myogenic cell lines, includ-
ing C2C12 cells, which are derived from mouse MSCs (Yaffe 
and Saxel, 1977). Thus, C2C12 cells represent an excellent cell 
culture model to study the proliferation and differentiation of 
MSC-derived myoblasts. Two families of transcription factors 
play critical roles in myogenesis. MRFs consist of Myf5, MyoD, 
MRF4, and myogenin. MRFs normally heterodimerize with gene 
E2A products (i.e., E12/E47) and bind to the consensus sequence 
of CANNTG (E box) in the promoters of many muscle-specifi  c 
genes (Molkentin and Olson, 1996; Sabourin and Rudnicki, 
2000; Tapscott, 2005). Id, a negative regulator for myogenesis, 
represses myogenic differentiation by binding to and sequestering 
either MRFs or E proteins, thus preventing MRFs from binding 
to the E box (Benezra et al., 1990). In addition to MRFs, myocyte 
enhancer–binding factor 2 (MEF2), which consists of MEF2A, 
2B, 2C, and 2D, is also essential for myogenesis (Black and 
Olson, 1998; McKinsey et al., 2002). MRFs and MEF2 physically 
interact with each other to synergistically activate many muscle-
specifi  c genes (Molkentin et al., 1995).
Many intracellular signaling molecules/pathways are 
known to modulate myogenic differentiation by regulating 
myogenin gene expression. Among them, the p38 MAPK, 
insulin-like growth factors/phosphatidylinositol 3-kinase/Akt, 
calcium/calmodulin-activated protein kinase, and calcineurin 
positively regulate myogenic differentiation (Coolican et al., 
1997; Zetser et al., 1999; Friday et al., 2000; McKinsey et al., 
2000; Tamir and Bengal, 2000; Wu et al., 2000; Xu and Wu, 
2000; Xu et al., 2002), whereas extracellular signal-regulated 
kinase (ERK) has dual roles: it inhibits differentiation at the 
early stage of differentiation but promotes myocyte fusion at the 
late stage of differentiation (Bennett and Tonks, 1997; Coolican 
et al., 1997; Wu et al., 2000). The Janus kinase (JAK)–signal 
transducer and activator of transcription (STAT) pathway repre-
sents one of the best-characterized cellular signaling pathways 
(O’Shea et al., 2002). Four JAKs (i.e., JAK1, 2, 3, and Tyk2) 
and seven STATs (i.e., STAT1, 2, 3, 4, 5a, 5b, and 6) have been 
Figure 1.  JAK1 knockdown accelerates myogenic 
differentiation. (A) WCEs from either C2C12 or primary 
myoblasts were subjected to Western blotting for vari-
ous markers. (B and C) C2C12 cells were transfected 
with various siRNAs as indicated. (B) Cells were ﬁ  xed 
at different time points as indicated and subjected to 
immunostaining for either myogenin or MHC. Phase-
contrast images of the same ﬁ   eld are also shown. 
(C) WCEs were prepared, and 20 μg WCE was 
subjected to immunoblotting. (D) Duplicate C2C12 
cells were transfected with siRNAs and the luciferase 
reporter constructs as indicated. 24 h after transfec-
tion, cells were switched to DM for another 24 h. 
WCEs were prepared and subjected to luciferase 
assays. Fold activation was calculated as the ratio of 
the luciferase activity of the JAK1-siRNA–transfected 
cells over that of the GFP-siRNA–transfected cells. 
The results are presented as mean ± SD (error bars). 
(E) Primary myoblasts were infected with adeno-
viruses expressing either JAK1-shRNA or lamin-shRNA. 
3 d after infection, cells were ﬁ  xed and subjected to 
double immunostaining for MyoD and MHC. (F) WCEs 
were prepared from C2C12 cells grown in GM or 
DM for 24 h. The endogenous JAK1 was immuno-
precipitated (IP) from 1 mg WCE and subjected to in 
vitro kinase assays. The HA antibody was used as a 
negative control. Bars, 100 μm.JAK1/STAT1 REPRESS MYOGENIC DIFFERENTIATION • SUN ET AL. 131
identifi  ed in the mouse and human genomes. Although it is well 
established that the JAK–STAT pathway plays essential roles 
in hematopoiesis and antimicrobial immune response (O’Shea 
et al., 2002), it remains unclear whether the JAK–STAT path-
way plays any essential role in myogenesis. Several lines of 
evidence suggest that the JAK–STAT pathway may have a 
role in myogenic differentiation. In regenerating rat muscles, 
proliferating myoblasts were found to contain higher levels of 
phosphorylated (i.e., active) STAT3 (Kami and Senba, 2002). 
In response to leukemia inhibitory factor (LIF), proliferating 
primary myoblasts grown in culture were also found to contain 
higher levels of phosphorylated STAT3 (Megeney et al., 1996; 
Spangenburg and Booth, 2002). Recently, MyoD was found to 
interact with STAT3 in an overexpression study (Kataoka et al., 
2003). Nevertheless, the aforementioned evidence was mainly 
correlative in nature, and none of these studies has addressed 
the question of whether and how the JAK–STAT pathway is 
involved in myogenic differentiation.
In this study, we report that the JAK1–STAT1–STAT3 
pathway plays dual roles in proliferating myoblasts: it is re-
quired for myoblast proliferation and also serves as a key 
checkpoint to prevent myoblasts from premature differentiation. 
Specifi  c knockdown of either JAK1 or STAT1 (to a lesser extent) 
reduces cell proliferation and induces precocious myogenic dif-
ferentiation. LIF engages the JAK1–STAT1–STAT3 pathway 
to promote proliferation and to prevent the premature differen-
tiation of myoblasts.
Results
JAK1 knockdown induces precocious 
myogenic differentiation in both C2C12 
and primary myoblasts
To explore the role of JAK1 in myogenic differentiation, we fi  rst 
examined its expression profi  les in both immortalized C2C12 
cells and primary myoblasts by Western blotting. As shown in 
Fig. 1 A, JAK1 was expressed in both C2C12 cells and primary 
myoblasts both before and after differentiation. To explore its 
functional role in myogenic differentiation, we fi  rst knocked 
down the endogenous JAK1 in C2C12 cells with siRNA. 
Surprisingly, compared with the control cells transfected with 
an siRNA against the gene encoding the jellyfi  sh GFP, a JAK1-
specifi  c siRNA dramatically accelerated myogenic differentia-
tion, as indicated by an increased number of myogenin-positive 
and myosin heavy chain (MHC)–positive cells and precocious 
formation of large multinucleated myotubes (Fig. 1 B). Western 
blotting confi  rmed that JAK1-siRNA was specifi  c and ef-
fective and potently induced the expression of myogenin and 
MHC (Fig. 1 C). In contrast, a JAK2-specifi  c siRNA inhibited 
C2C12 differentiation, as indicated by decreased myogenin and 
MHC expression levels compared with the GFP-siRNA con-
trol (Fig. 1 C). Consistently, JAK1-siRNA greatly activated two 
myogenic luciferase reporter genes driven by a fragment of the 
native myogenin promoter and muscle creatine kinase (MCK) 
promoter (i.e., G133-luc and MCK-luc, respectively; Fig. 1 D). 
To fi  nd out whether the JAK1 knockdown had a similar effect 
on primary myoblasts, we infected the primary myoblasts 
(i.e., MyoD
+) with adenoviruses expressing either the JAK1-
specifi  c short hairpin RNA (shRNA) or human lamin-specifi  c 
shRNA (control). Compared with cells infected with lamin-
shRNA, those infected with JAK1-shRNA underwent potent and 
accelerated differentiation, as manifested by the considerably 
increased number and size of MHC-positive myotubes (Fig. 1 E). 
In addition, we determined the kinase activity of the endo-
genous JAK1 in C2C12 cells before and after differentiation. 
We found that the kinase activity of JAK1 decreased upon 
differentiation (Fig. 1 F).
JAK1 and the ERK pathway cooperate 
to repress myogenic differentiation
Because the knockdown of JAK1 stimulates myogenic differen-
tiation (Fig. 1), we next asked what happens if we overexpress 
JAK1 in myogenic cells. We generated stable C2C12 cells ex-
pressing either the wild-type JAK1 or an empty vector and 
subjected these cells to differentiation. As shown in Fig. 2 A, 
upon differentiation, cells overexpressing JAK1 had much lower 
myogenin levels and undetectable MHC compared with those 
with an empty vector. Consistently, the overexpression of JAK1 
inhibited the activity of MCK-luc (Fig. 2 B). The inhibitory role 
of JAK1 at the early phase of myogenic differentiation was remi-
niscent of that of the ERK pathway (Bennett and Tonks, 1997; 
Coolican et al., 1997; Wu et al., 2000). To study the potential cross 
talk between the two pathways, we fi  rst examined the effect of 
Figure 2.  JAK1 and the ERK pathway cooperate to repress myogenic 
differentiation. (A) C2C12 cells stably expressing either a wild-type Flag-
JAK1 or an empty vector (pcDNA3) were allowed to differentiate in DM for 
various times. 20 μg WCE was subjected to immunoblotting using various 
antibodies as indicated. (B) Duplicate C2C12 cells were cotransfected 
with MCK-luc together with either an empty vector or the wild-type Flag-
JAK1. 24 h after transfection, cells were switched to DM for another 24 h 
before harvest. WCEs were subjected to luciferase analysis. Fold change 
was calculated as the ratio of the luciferase activity of cells transfected with 
Flag-JAK1 over that with an empty vector. The results are presented as 
mean ± SD (error bars). (C and D) C2C12 cells were transfected with either 
cDNA expression vectors (C) or various siRNAs (D) as indicated. (C) Cells 
were grown in GM for 24 h and in DM for another 24 h. (D) 10 μM 
DMSO or U0126 was added when cells were switched to DM and kept for 
12 h. Cells were harvested, and WCEs were subjected to immunoblotting. 
+ denotes that cells were transfected with the construct indicated on the 
left; ca, constitutively active. The white line indicates that intervening lanes 
have been spliced out.JCB • VOLUME 179 • NUMBER 1 • 2007  132
JAK1-siRNA on the levels of the active ERKs (i.e., phospho-
ERK) in C2C12 cells. As a control, we also examined the status 
of the active p38 MAPK and Akt, both of which are indispens-
able for myogenic differentiation (Zetser et al., 1999; Wu et al., 
2000; Xu and Wu, 2000). We found that the JAK1 knockdown 
did not affect the levels of the active ERKs, p38 MAPKs, and 
Akt in C2C12 cells (unpublished data), suggesting that the potent 
prodifferentiation effect of JAK1-siRNA was not mediated by 
these pathways. We then tested whether JAK1 cooperates with 
the ERK pathway to repress myogenic differentiation. Although 
cells overexpressing either MEK1∆N4, which constitutively 
activates ERK (Mansour et al., 1996), or JAK1 already led to a 
reduced expression of myogenin, cells overexpressing both fur-
ther repressed myogenin expression (Fig. 2 C). Conversely, cells 
treated with either JAK1-siRNA or U0126, a specifi  c inhibitor 
for the ERK pathway (Favata et al., 1998), differentiated faster 
as indicated by the accelerated induction of myogenin (Fig. 2 D, 
compare lanes 1 and 3 with lane 2). Importantly, cells treated 
with both JAK1-siRNA and U0126 together had a more potent 
myogenin induction than either treatment alone (Fig. 2 D, lane 4). 
Our data suggest that JAK1 and the ERK pathway cooperate to 
repress early myogenic differentiation.
Knockdown of JAK1 induces the 
expression of MyoD and MEF2, accelerates 
the down-regulation of Id1, and activates 
MEF2-dependent gene transcription
To uncover the molecular mechanisms underlying the pro-
differentiation effect of JAK1-siRNA, we examined several key 
Figure 3.  JAK1-siRNA induces the accelerated expression of MyoD and 
MEF2, promotes a faster down-regulation of Id1, and enhances MEF2-
dependent gene transcription. (A and B) C2C12 cells were transfected with 
various siRNAs as indicated. 24 h after transfection, cells were induced to 
differentiate in DM for various times as indicated. WCEs were prepared 
and subjected to immunoblotting. (C and D) Duplicate C2C12 cells were 
cotransfected with the luciferase reporter constructs together with either 
siRNAs (C) or cDNAs (D) as indicated. Cells were induced to differentiate 
in DM for 12 h before harvest. WCEs were subjected to luciferase assays. 
Fold activation or change was calculated as described in Figs.1 and 2. 
The results are presented as mean ± SD (error bars).
Figure 4.  JAK1-siRNA inhibits myoblast proliferation. C2C12 cells were 
transfected with either GFP-siRNA or JAK1-siRNA as indicated. (A) WST-1 
reagent was added to cells at different times as indicated, and absorbance 
at 480 nm was measured by a plate reader. The experiment was per-
formed in triplicate, and the results are presented as mean ± SD (error 
bars). (B and C) 30 h after siRNA transfection, 10 μM BrdU was added for 
1 h (B). Cells were ﬁ  xed and subjected to immunostaining using antibodies 
against BrdU. Nuclei were counterstained with DAPI, and images were 
taken and analyzed by ﬂ   uorescent microscopy. The percentage of cells 
positive for BrdU staining was calculated based on cells from ﬁ  ve randomly 
chosen ﬁ  elds (10× magniﬁ  cations). The results are presented as mean ± SD. 
(C, top) Cells were trypsinized, ﬁ   xed, and subjected to FACS analysis. 
(bottom) Cells were treated with nocodazole for 24 h followed by FACS 
analysis. (D) WCE was prepared at different times as indicated, and 30 μg 
WCE was subjected to immunoblotting analysis.JAK1/STAT1 REPRESS MYOGENIC DIFFERENTIATION • SUN ET AL. 133
players involved in early myogenic differentiation. As shown 
in Fig. 3 A, the protein levels of both MyoD and MEF2 were 
clearly induced by JAK1-siRNA at the early stage of differenti-
ation. This induction mainly occurred at the transcription level, 
as the mRNA levels of MyoD, MEF2A, 2C, and 2D were also 
induced by JAK1-siRNA as judged by semiquantitative RT-
PCR (unpublished data). In contrast, Id1, a known negative reg-
ulator for myogenic differentiation (Benezra et al., 1990), was 
down-regulated at a faster rate in the presence of JAK1-siRNA 
(Fig. 3 B). In addition, we also examined the impact of JAK1-
siRNA on both MyoD and MEF2-dependent gene transcription. 
Although JAK1-siRNA had less effect on the activity of 4xRE-
luc, a MyoD-dependent reporter, it substantially elevated the 
activity of 3xMEF2-luc, an MEF2-dependent reporter (Fig. 3 C). 
Consistently, the overexpression of JAK1 greatly inhibited 
the MEF2-dependent gene transcription but had less effect on 
MyoD-dependent gene transcription (Fig. 3 D).
Knockdown of JAK1 inhibits myoblast 
proliferation
While we were studying the impact of JAK1-siRNA on myo-
genic differentiation, we also noticed that JAK1-siRNA consid-
erably affected cell proliferation. In a time course experiment, 
we found that C2C12 cells transfected with JAK1-siRNA 
displayed a reduced proliferation rate compared with the con-
trol cells transfected with GFP-siRNA (Fig. 4 A). Similarly, a 
lower percentage of C2C12 cells treated with JAK1-siRNA in-
corporated BrdU compared with cells treated with GFP-siRNA 
(Fig. 4 B). To closely examine the effect of JAK1-siRNA on 
the cell cycle, we subjected the siRNA-treated C2C12 cells to 
fl  ow cytometry analysis. We found that a higher proportion of 
cells transfected with JAK1-siRNA were arrested in G1 phase 
compared with the GFP-siRNA–transfected control cells no 
matter whether nocodazole was used or not (to reduce the in
terference from either untransfected cells or cells already in 
S or early G2 phase; Fig. 4 C). To investigate the underlying 
molecular mechanisms, we examined several key cell cycle 
regulators. Although JAK1-siRNA had no obvious effect on the 
levels of CDK4 and total Rb, it induced p21Cip1 and p27Kip1, 
two prominent CDK2 inhibitors, in both proliferating cells as 
well as in cells undergoing early differentiation (Fig. 4 D). 
Consistently, the levels of Rb phosphorylation at Ser795, a site 
mainly phosphorylated by CDK2 and CDK4 (Ortega et al., 
2003), also decreased in cells with elevated p21Cip1 and 
p27Kip1 (Fig. 4 D).
STAT1 speciﬁ  cally mediates the effect 
of JAK1 during myogenic differentiation
Although our aforementioned data indicated that JAK1 nega-
tively regulates myogenic differentiation, it remained unclear 
whether its kinase activity is required in this process. To 
address this issue, we generated two siRNA-resistant JAK1 
constructs: one encoding the wild-type protein and the other 
encoding a kinase-dead mutant. We then transfected C2C12 
cells with JAK1-siRNA together with expression vectors en-
coding either the wild-type JAK1 (i.e., siRNA sensitive) or the 
siRNA-resistant JAK1. As shown in Fig. 5 A, although both 
forms of the siRNA-resistant JAK1 were expressed at high 
Figure 5.  STAT1 mediates the antidifferentiation effect of JAK1. (A) C2C12 cells were transfected with JAK1-siRNA together with various forms of 
JAK1 cDNA. After 24 h in DM, cells were harvested, and WCEs were subjected to immunoblotting. R, siRNA resistant; KR, kinase-dead mutant of JAK1 
with Lys896 replaced by Arg. (B) C2C12 cells were transfected with various siRNAs as indicated. WCEs were prepared from cells grown in DM 
for 12 h and subjected to immunoblotting. ns, nonspeciﬁ  c band. (C) 100 μg WCE prepared from primary myoblasts harvested at different times was 
subjected to immunoblotting. (D) Freshly isolated primary myoblasts were transfected with either GFP-siRNA or STAT1-siRNA. 24 h after transfection, 
cells were ﬁ  xed and subjected to immunostaining for MHC (top). The nuclei of the cells were counterstained with DAPI (bottom). The percentage of 
MHC-positive cells was calculated based on cells from ﬁ  ve randomly chosen ﬁ  elds. Error bars represent SD. (E) C2C12 cells were cotransfected 
with various siRNAs and cDNA expression vectors as indicated. After 36 h in DM, cells were harvested, and WCEs were subjected to immunoblotting. 
Bar, 100 μm.JCB • VOLUME 179 • NUMBER 1 • 2007  134
levels in the presence of JAK1-siRNA, only the one retaining 
the kinase activity effectively reversed the prodifferentiation 
effect of JAK1-siRNA, as indicated by reduced myogenin 
expression and a complete lack of MHC expression (lane 2). 
This suggested that the kinase activity of JAK1 is essential for 
its repressive effect during myogenic differentiation. To identify 
downstream mediators of JAK1 in myogenic differentiation, 
we focused on STATs that are well-established downstream 
targets and mediators of JAKs (O’Shea et al., 2002). We fi  rst 
designed siRNAs to individually knock down STATs that 
are present in C2C12 cells (i.e., STAT1, 2, 3, 5A, and 5B as 
judged by RT-PCR; unpublished data). Among them, only 
STAT1-siRNA led to a precocious induction of myogenin 
(Fig. 5 B), an effect similar to that of JAK1-siRNA (Fig. 1 C). 
In contrast, the siRNAs against STAT3 and other STATs in-
hibited myogenin expression (Fig. 5 B and unpublished data). 
Transfection of C2C12 cells with a second set of siRNAs 
targeting a different region of STAT1 and STAT3 generated 
similar results (unpublished data). To extend the study to primary 
myoblasts, we fi  rst confi  rmed that STAT1 was expressed in 
 primary myoblasts both before and after differentiation (Fig. 5 C). 
Consistently, primary myoblasts transfected with STAT1-siRNA 
differentiated faster than those with GFP-siRNA, as indicated by 
a substantially increased number of MHC-positive cells (Fig. 5 D). 
Furthermore, we found that the repression of myogenin and 
MHC mediated by the overexpression of JAK1 could be rescued 
by STAT1-siRNA but not by STAT2-siRNA (Fig. 5 E).
LIF promotes proliferation and inhibits 
the differentiation of C2C12 cells via 
JAK1–STAT1–STAT3
LIF is a known mitogen for both primary myoblasts and 
C2C12 cells (Austin and Burgess, 1991; Megeney et al., 1996; 
Spangenburg and Booth, 2002). Because JAK1 is also required 
for myoblast proliferation (Fig. 4), naturally, we wanted to test 
whether LIF promotes myoblast proliferation through JAK1 
and STAT1. When C2C12 cells were exposed to LIF, cell pro-
liferation was clearly accelerated as measured by WST-1 assays 
(Fig. 6 A). To reveal the composition of the STAT complex 
  induced by LIF, we performed electrophoretic mobility shift 
Figure 6.  LIF stimulates proliferation and re-
presses differentiation via JAK1–STAT1–STAT3. 
(A) C2C12 cells were treated with either vehi-
cle (i.e., PBS) or LIF. At different time points, 
cells in 96-well plates (ﬁ  ve wells/time point/
sample) were subjected to WST-1 assays. The 
absorbance at 480 nm was plotted against 
time. The results are presented as mean ± SD 
(error bars). (B) Cells were treated with LIF for 
15 min before harvest. 20 μg WCE was sub-
jected to EMSA. NS, nonspeciﬁ   c. (C) Cells 
were treated with LIF for various times as indi-
cated. (D) Cells were ﬁ   rst transfected with 
either GFP-siRNA or JAK1-siRNA followed by 
LIF treatment for 15 min. (E) C2C12 cells were 
treated with LIF for various times. (F) Cells were 
ﬁ   rst transfected with various siRNAs as indi-
cated followed by LIF treatment for 12 h in DM. 
WCEs from C–F were subjected to immuno-
blotting. (G) Cells in 96-well plates were trans-
fected with siRNAs followed by LIF treatment 
for various times before being subjected to 
WST-1 assays. The results are plotted and 
  presented the same way as in A. The plus and 
minus signs indicate that the reagents listed on 
the left were present and absent, respectively. 
The white line indicates that intervening lanes 
have been spliced out.JAK1/STAT1 REPRESS MYOGENIC DIFFERENTIATION • SUN ET AL. 135
  assays (EMSAs) using an oligonucleotide containing a consensus 
STAT-binding site as a probe (O’Shea et al., 2002). As shown 
in Fig. 6 B, we did detect specifi  c STAT complexes. Supershift 
assays with several STAT-specifi  c antibodies revealed that the 
LIF-induced STAT complexes mainly consist of STAT1 and 
STAT3 but not STAT2 (Fig. 6 B, lanes 6 and 7). Furthermore, 
JAK1, STAT1, and STAT3 were all activated as early as 10 min 
after LIF treatment, which was evident by an increase in their 
tyrosine-phosphorylated (i.e., active) forms even though their 
total protein levels did not change much (Fig. 6 C and unpub-
lished data). Moreover, the LIF-induced tyrosine phosphory-
lation of STAT1 and STAT3 could be reduced by JAK1-siRNA 
but not by JAK2-siRNA, suggesting that JAK1 mediates the 
LIF-induced phosphorylation of STAT1 and STAT3 in C2C12 
cells (Fig. 6 D). In addition to its role in myoblast proliferation, 
LIF was also known to inhibit myogenin expression and myo-
genic differentiation (Jo et al., 2005). To uncover the  underlying 
mechanisms, we examined the expression status of MyoD and 
MEF2. We found that LIF repressed the expression of MEF2 in 
both proliferating myoblasts and cells undergoing differentia-
tion (Fig. 6 E). In contrast, LIF had less effect on the expression 
levels of MyoD (unpublished data). Importantly, LIF-mediated 
down-regulation of both MEF2 and myogenin was effi  ciently 
rescued by JAK1-siRNA and was partially rescued by STAT1-
siRNA (Fig. 6 F). Furthermore, LIF-induced C2C12 proliferation 
was also greatly inhibited by JAK1-siRNA and, to a lesser extent, 
the siRNAs against either STAT1 or STAT3 (Fig. 6 G). Thus, 
our aforementioned data suggested that JAK1–STAT1–STAT3 
act downstream of LIF and mediate its effect on myoblast pro-
liferation and differentiation.
JAK1/STAT1/STAT3 are up-regulated 
and activated in cardiotoxin-induced 
regenerating muscles
Because MSC-derived primary myoblasts are mainly responsi-
ble for injury-induced muscle regeneration, as an initial attempt, 
we examined the status of JAK1, STAT1, and STAT3 in regen-
erating tibialis anterior (TA) muscles in response to cardiotoxin-
induced muscle injury (Charge and Rudnicki, 2004). In this 
injury-induced muscle regeneration model, the satellite cell–
derived myoblasts actively proliferated in the fi  rst 2–3 d (Yan 
et al., 2003). A majority of myoblasts started to differentiate by 
day 3 as indicated by a peak expression of myogenin (Fig. 7 A). 
The damaged area was largely repaired by day 15 (Yan et al., 
2003). Consistently, we found that the total levels of both JAK1 
and STAT1 increased upon injury, peaked at day 3 after injury, 
and gradually decreased afterward (Fig. 7 A). Importantly, both 
the kinase activity of JAK1 and levels of the active STAT1 
increased as early as 1 d after injury (Fig. 7 B). As to STAT3, 
  although its total levels did not change much in response to 
the injury, the levels of active STAT3 substantially increased 1 d 
after injury and peaked at day 3 (Fig. 7 A).
Figure 7.  JAK1/STAT1/STAT3 were activated during cardiotoxin-induced muscle regeneration. (A) After the injection of cardiotoxin (CTX), TA muscles 
were isolated at different time points as indicated. WCEs from TA muscles were prepared, and 200 μg WCE was subjected to immunoblotting. (B) WCEs 
from control and regenerating TA muscles were separately subjected to immunoprecipitation (IP) with either the anti-JAK1 antibody (top two panels) or the 
anti-STAT1 antibody (bottom two panels). The immunoprecipitated JAK1 was subjected to both protein kinase assays (top) and immunoblotting (second 
panel), whereas the immunoprecipitated STAT1 was only subjected to immunoblotting (third and fourth panels). (C) A schematic on injury-induced muscle 
regeneration. Key molecules/pathways acting at different stages of regeneration are indicated.JCB • VOLUME 179 • NUMBER 1 • 2007  136
Discussion
The role of the JAK1–STAT1–STAT3 
pathway in both myoblast differentiation 
and muscle regeneration
In this study, we provide evidence showing that the JAK1– 
STAT1–STAT3 pathway has two distinct roles in myogenic 
differentiation: on one hand, it is required for myoblast pro-
liferation as a result of its involvement in regulating the ex-
pression of p21Cip1, p27Kip1, and Id1. On the other hand, it 
prevents myoblasts from premature differentiation by actively 
repressing genes essential for differentiation (e.g., MyoD, MEF2, 
and myogenin). In this sense, the status of the JAK1–STAT1–
STAT3 pathway can be viewed as a key checkpoint for dif-
ferentiation, as shutdown of this pathway is a prerequisite for 
myoblasts to initiate the differentiation program. The diverse 
roles of the JAK1–STAT1–STAT3 pathway are especially 
important during injury-induced muscle regeneration. MSCs 
normally undergo three distinct phases during injury-induced 
regeneration: activation, proliferation, and differentiation (Fig. 
7 C). In the activation phase, the quiescent MSCs are activated 
by an ill-defi  ned mechanism in response to injury. Certain 
cytokines/chemokines released by infl  ammatory cells could 
potentially serve as the trigger (Tidball, 2005; Wagers and 
Conboy, 2005). In the proliferation phase, the activated MSCs 
actively proliferate to generate a suffi  cient number of myo-
blasts. Premature differentiation of myoblasts is undesired at 
this stage. In the fi  nal differentiation phase, myoblasts differ-
entiate and fuse with existing myofi  bers to repair the damaged 
muscles. Based on the properties of the JAK1–STAT1–STAT3 
pathway in myoblast cultures, we expect that the pathway 
mainly operates in the proliferation phase during muscle re-
generation. Consistently, our preliminary study shows that 
JAK1, STAT1, and STAT3 are all activated in regenerating 
muscles at a time when myoblasts actively proliferate (Fig. 7, 
A and B). Because the invading infl  ammatory cells, including 
neutrophils, macrophages, and T cells, are also present in re-
generating muscles, it remains to be further clarifi  ed whether 
the changes in JAK1–STAT1–STAT3 specifi  cally occur in pro-
liferating myoblasts.
The distinct roles of STAT1 and STAT3 
in myoblast proliferation and differentiation
Although STAT3 is commonly associated with cell prolifera-
tion in many different cell types, STAT1 is rarely associated 
with proliferation (O’Shea et al., 2002). In fact, the activation 
of STAT1 often reduces cell proliferation (Chin et al., 1996; 
O’Shea et al., 2002). Therefore, it is quite unique that STAT1 
is required for myoblast proliferation. Although it remains 
unclear what dictates these different outcomes, presumably, it 
is a cell context–dependent phenomenon, which implies that 
STAT1 has to cooperate with other molecules/pathways to 
bring about different effects on cell proliferation. The involve-
ment of STAT3 in myoblast proliferation is supported by our 
following fi  ndings: (1) STAT3 and STAT1 form complexes in 
response to LIF stimulation and (2) the knockdown of STAT3 
reduces LIF-induced myoblast proliferation. Consistently, an 
earlier study showed that LIF activates STAT3 in proliferating 
myoblasts (Megeney et al., 1996). Unexpectedly, the knock-
down of STAT3 does not accelerate differentiation the same 
way as the knockdown of STAT1 does (Fig. 5 B). A possible 
explanation is that STAT3 may be required for both the prolif-
eration and differentiation of myoblasts, which is supported by 
our fi  ndings that the levels of active STAT3 gradually increase 
during differentiation in C2C12 cells (unpublished data) and 
that the knockdown of STAT3 inhibits differentiation (Fig. 5 B). 
It is likely that STAT3 may function at different phases of dif-
ferentiation by associating with different partners. Further 
investigation is needed to clarify the role of STAT3 in myo-
genic differentiation.
LIF utilizes the JAK1–STAT1–STAT3 
pathway to regulate the proliferation 
and differentiation of myoblasts
So far, several cytokines and growth factors, including LIF, 
hepatocyte growth factor, and basic FGF, have been shown to 
stimulate the proliferation of myoblasts in vitro (Charge and 
Rudnicki, 2004; Dhawan and Rando, 2005). The only in vivo 
data came from the LIF knockout mice. It was shown that 
  injury-induced muscle regeneration is delayed in LIF
−/− mice and 
that the defect can be rescued by the injection of exogenous LIF 
(Kurek et al., 1997). Thus, LIF is essential for the proliferation 
of myoblasts both in vivo and in vitro. As a member of the IL-6 
family of cytokines, LIF is known to exert its diverse functions 
mainly through the JAK–STAT pathway (Heinrich et al., 2003; 
Metcalf, 2003). Consistent with this notion, we demonstrate here 
that LIF specifi  cally utilizes the JAK1–STAT1–STAT3 pathway 
to regulate the proliferation and differentiation of   myoblasts. 
It remains to be seen whether other members of the IL-6 family 
are capable of regulating myogenic differentiation through 
similar mechanisms.
Multiple JAK–STAT pathways are operative 
in myoblasts with opposing effects
Although several different JAK family members are usually 
associated with the same receptor complex (e.g., JAK1 and 
JAK2 associate with the α and β chains of interferon-γ recep-
tor, respectively) in cytokine signaling (Leonard and O’Shea, 
1998), JAK1 seems to form homodimers during myogenic 
differentiation, as the knockdown of either JAK2 or Tyk2, the 
remaining two members of the JAK family present in both 
primary and immortalized myoblasts, has the opposite effect 
as compared with that of JAK1 (Fig. 1 C and unpublished data). 
This suggests that multiple JAK–STAT pathways function to 
control the proliferation and differentiation of myoblasts with 
opposing effects. In the future, it is essential for us to under-
stand how these different JAK–STAT pathways coordinate 
with each other to control myogenic differentiation and how 
they cross talk with other signaling pathways. With such 
knowledge, it is possible to accelerate injury-induced muscle 
regeneration by differentially modulating different JAK–STAT 
pathways with small molecules. We believe that our work 
has provided a new direction in studying the biology of muscle 
stem cells.JAK1/STAT1 REPRESS MYOGENIC DIFFERENTIATION • SUN ET AL. 137
Materials and methods
Cell lines, DNA constructs, and reagents
C2C12 cells were maintained in DME with 20% FBS, 100 U/ml penicillin, 
and 100 μg/ml streptomycin (also called growth medium [GM]) in a 
37°C incubator with 5% CO2. To induce differentiation, cells were grown 
in DME containing 2% horse serum (also called differentiation medium 
[DM]). Flag-JAK1 (human) and two STAT1 constructs (i.e., the wild-type 
and Y701F mutant) were gifts from Z. Wen (Hong Kong University of 
Science and Technology, Hong Kong, China). G133-luc, MCK-luc, 4xRE-
luc, and 3xMEF2-luc were described previously (Xu et al., 2002; Sun 
et al., 2004). Silent mutation was introduced into Flag-JAK1(wild type) and 
the kinase-dead Flag-JAK1(K896R) constructs to generate siRNA-resistant 
R-Flag-JAK1(wild type) and R-Flag-JAK1(K896R), respectively, using the 
oligonucleotide 5′-A  C  C  C  G  A  A  A  G  C  G  G  C  G  G  C  A  A  T  C  A  C  A  T  A  G  C  T  G  A  T  C  T-
G  A  A  A  A  A  G  -3′ (top strand). U0126 and LIF were purchased from Calbio-
chem and Chemicon, respectively.
Antibodies, immunoblotting, immunostaining, and microscopic imaging
The sources of the antibodies used in this study are listed as follows: JAK1, 
JAK2, and STAT1 were purchased from Upstate Biotechnology; JAK1, Rb, 
CDK4, myogenin, MyoD, Id1, p21Cip1, p27Kip1, β-actin, and MEF2 were 
obtained from Santa Cruz Biotechnology, Inc.; anti-Flag was purchased from 
Sigma-Aldrich; phosphor-Rb (Ser795), phosphor-JAK1 (Tyr1022/1023), 
phopho-STAT1 (Tyr705), and phosphor-STAT3 (Tyr705) were obtained 
from Cell Signaling; and MHC was purchased from   Developmental Studies 
Hybridoma Bank. Polyclonal STAT3 antibody was a gift from Z. Wen. 
Immunoblotting was performed according to standard procedures (Xu 
et al., 2002). For immunostaining, FITC- and rhodamine-conjugated 
second  ary antibodies and DAPI were used to label selected molecules and 
to counterstain the nuclei, respectively. The images were acquired at room 
temperature by a CCD camera (Spot RT; Diagnostic Instruments) mounted 
on a ﬂ  uorescent microscope (IX70; Olympus) using SPOT software (version 
4.0.9; Diagnostic Instruments). UPlanFL 10× NA 0.3 and LCPlanFL 20× 
NA 0.4 objectives (Olympus) were used. The brightness and contrast of the 
images were adjusted by Photoshop 6.0 (Adobe).
Cell lysis and preparation of soluble WCEs
After removal of the culture medium, cells were washed once with PBS 
  before addition of the lysis buffer (50 mM Hepes, pH 7.6, 1% vol/vol Triton 
X-100, 150 mM NaCl, 1 mM EGTA, 1.5 mM MgCl2, 100 mM NaF, 20 mM 
p-nitrophenylphosphate, 20 mM β-glycerophosphate, 50 μM sodium 
vanadate, 2 mM DTT, 0.5 mM PMSF, 2 μg/ml aprotinin, 0.5 μg/ml 
leupeptin, and 0.7 μg/ml pepstatin). Cells were lysed for 10 min at 4°C 
followed by centrifugation to remove the insoluble cell debris. The concen-
tration of the whole cell extracts (WCEs) was determined by a protein assay 
reagent (Bio-Rad Laboratories).
Preparation of primary myoblasts
Isolation of primary MSCs was performed as described previously with 
  minor modiﬁ  cations (Allen et al., 1997). In brief, skeletal muscles of 2-mo-old 
C57BL/6J mice were isolated, minced, and digested in 1.25 mg/ml prote-
ase type XVII (Sigma-Aldrich) for 1.5 h in a 37°C water bath. Satellite cells 
were puriﬁ   ed by discontinuous Percoll gradient centrifugation and col-
lected from the interface of 20 and 60% Percoll. Puriﬁ  ed satellite cells were 
then cultured in GM (DME containing 20% FBS and 2% chicken embryo 
extracts) in culture dishes coated with 4 mg/ml Matrigel (BD Biosciences) 
to generate primary myoblasts. Myoblasts were induced to differentiate in 
DM (DME with 5% horse serum).
Cardiotoxin-induced muscle injury and regeneration
TA muscles of 6–8-wk-old C57BL/6 mice were injected with 25 μl of 10 μM 
cardiotoxin (Sigma-Aldrich). At different time points after injury, mice were 
killed by cervical dislocation, and the TA muscles were surgically isolated 
and homogenized in the lysis buffer followed by centrifugation to remove 
insoluble debris. Uninjured TA muscles were used as a control.
siRNA transfection and adenovirus preparation and infection
To deliver oligonucleotide-based siRNA, 50–70% conﬂ  uent C2C12 cells were 
transfected with 100 nM siRNA using LipofectAMINE 2000 (Invitrogen). 
The following siRNAs were synthesized at Dharmacon, Inc.: JAK1 (5′-G  C  C  U-
G    A  G  A  G  U  G  G  A  G  G  U  A  A  C  -3′), JAK2 (5′-G  C  A  A  A  C  C  A  G  G  A  A  U  G  C  U  C  A  A  -3′), 
STAT1 (5′-G  C  G  U  A  A  U  C  U  C  C  A  G  G  A  U  A  A  C  -3′), STAT3 (5′-C  T  G  G  A  T  A  A  C  T  T-
C  A  T  T  A  G  C  A  -3′), and enhanced GFP (5′-G  C  U  G  A  C  C  C  U  G  A  A  G  U  U  C  A  U  C  -3′). 
To generate shRNA from an adenoviral vector, we used the Block-iT RNAi 
expression kit (Invitrogen) according to the manufacturer’s instructions. 
20 μl of viruses ( 10
8 plaque-forming U/ml) was used to infect 60% 
conﬂ  uent primary myoblasts in 35-mm plates.
In vitro immune complex kinase assays
JAK1 was ﬁ  rst immunoprecipitated from 1 mg WCEs, washed exten-
sively, and reconstituted in the kinase buffer (10 mM Hepes, pH 7.4, 
50 mM NaCl, 5 mM MgCl2, 5 mM MnCl2, 100 μM Na3VO4, and 
0.25 mCi/ml γ-[
32P]ATP). The reaction was incubated at room temperature 
for 30 min and terminated by adding sample loading dye. The reaction 
was separated on 8% SDS-PAGE, and the gel was dried and subjected 
to autoradiography.
WST-1 assays
C2C12 cells were ﬁ  rst seeded into 96-well plates in triplicate at a density 
of 10
3 cells/well followed by transfection with various siRNAs the next 
day. WST-1 reagent (Boehringer) was then added at ﬁ  xed time points 
according to the manufacturer’s instructions. The absorbance at 480 nm was 
measured using a microtiter plate reader.
EMSA
EMSA was performed as described previously (Chan et al., 2003). The top 
strand sequence of the probe is 5′-G  T  C  G  A  C  A  T  T  T  C  C  C  G  T  A  A  A  T  C  -3′.
BrdU labeling and FACS analysis
An in situ cell proliferation kit (Roche) was used to measure BrdU incorpo-
ration. Cells were labeled with 10 μM BrdU for 1 h. Nuclei incorporating 
BrdU were visualized by ﬂ  uorescein-conjugated monoclonal anti-BrdU 
antibody. For FACS analysis, cells were trypsinized, washed with PBS, ﬁ  xed 
in 70% ethanol for 30 min on ice, harvested by centrifugation at 300 g 
for 5 min, and resuspended in 400 μl PBS. To stain the DNA, 5 μl prop-
idium iodide (5 mg/ml) and 5 μl RNase A (10 mg/ml) were added to the 
solution. Cells were incubated at 37°C for 30 min before being subjected 
to FACS analysis.
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